Business news from Yahoo
Nearly half of lymphoma patients treated with Gilead Sciences Inc's Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to data presented on Saturday. Out of 101 patients teated with Yescarta for an aggressive blood cancer known as refractory large B-cell lymphoma in the study, 47 were still alive at least three years later, the data presented at the American Society of Hematology meeting in Orlando showed. "We are delivering towards our goal of potentially life-saving therapy for many patients who previously faced limited treatment options," Christi Shaw, chief executive of Gilead's Kite unit, said in a statement.
China's exports in November shrank for the fourth consecutive month, underscoring persistent pressures on manufacturers from the Sino-U.S. war but growth in imports may be a sign that Beijing's stimulus steps are helping to stoke demand. The 17-month long trade dispute has heightened the risks of a global recession and fueled speculation that China's policymakers could unleash more stimulus as growth in the world's second-largest economy cooled to nearly 30-year lows. The better-than-expected import data may point to firming domestic demand after factory activity showed surprising signs of improvement recently, although analysts have noted the recovery could be difficult to sustain amid trade risks.
It’s election week… The Tories remain ahead in the polls and the predictions, with the odds also supporting the Pound. Could it be plain sailing?
The judge's ruling cited "imminent and irreparable damage" to the 100-acre National Butterfly Center.